COMPASS Pathways
COMPASS Pathways develops COMP360, a synthetic psilocybin treatment in late-stage trials for treatment-resistant depression and PTSD.
10-KSep 25Latest SEC filing
Aug 5Latest story
Sign inSign inCOMPASS Pathways develops COMP360, a synthetic psilocybin treatment in late-stage trials for treatment-resistant depression and PTSD.